Oncolytics Biotech Completes GOBLET Study Enrollment, Awaits Key Data Readouts

  • Oncolytics Biotech completed enrollment in Cohort 5 of the GOBLET study earlier this year and expects the final PanCAN grant payment this quarter.
  • Final results from Cohort 4 are expected in Q4 2026, with initial Cohort 5 results anticipated in the first half of 2027.
  • The company will use clinical data to guide its strategy for combining pelareorep with checkpoint inhibitors in gastrointestinal and other tumors.
  • All cohorts that enrolled the required number of patients met pre-specified success criteria for efficacy.

Oncolytics Biotech is advancing its immunotherapy pelareorep through the GOBLET study, which evaluates its potential in multiple gastrointestinal cancers. The completion of enrollment and upcoming data readouts are critical for guiding the company's strategy in combining pelareorep with checkpoint inhibitors. The study's success criteria being met across cohorts suggest promising efficacy, which could position Oncolytics for further partnerships and regulatory advancements in the competitive oncology space.

Data Readout Timing
Whether the initial Cohort 5 results in H1 2027 will meet or exceed efficacy expectations, particularly for pancreatic cancer.
Strategic Focus
How Oncolytics will prioritize the combination of pelareorep with checkpoint inhibitors across different tumor types.
Partnership Dynamics
The pace at which Oncolytics secures additional strategic partnerships to accelerate pelareorep's development.